Haiyang Yun
Group Leader

Dr. Haiyang Yun, Ph.D.

Haiyang Yun was born in Henan, P.R.China in 1983. He holds a Bachelor’s Degree in Clinical Medicine from Tongji University (China, 2000-2005) and a Master’s Degree in Internal Medicine from Shanghai Jiao Tong University (China, 2005-2008). He enrolled in the Molecular Medicine PhD program at Hannover Medical School in Germany, and completed his doctoral thesis under the supervision of Prof. Michael Heuser in 2013. Subsequently Dr. Yun joined Prof. Brian Huntly’s lab at University of Cambridge, being a Postdoc Researcher from 2014 to 2018 to investigate high dimensional chromatin remodelling dynamics during leukemia evolution. Afterwards he returned to Germany and later became a Senior Scientist in the department led by Prof. Carsten Müller-Tidow at University Hospital Heidelberg. In Heidelberg he initiated and led a new project to identify chromatin-associated RNA molecules with essential roles in leukemia maintenance. Dr. Yun was promoted to a Group Leader position in the same department shortly after he acquired DFG research funding with the module “Temporary Positions for Principal Investigators” in 2022. Since then he has led a team to identify enhancer RNAs functioning on transcriptional regulation via chromatin modulation in leukemia. In January 2024, Dr. Yun assumed the independent Group Leader position at Robert the Robert Bosch Center for Tumor Diseases. His new role will be dedicated to the research on decoding complex functional epigenomics in hematological malignancies.

Relevant own publications

  • Yun H#, Zoller J, Zhou F, Rohde C, Liu Y, Blank MF, Göllner S, Müller-Tidow C#. The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance. Leukemia. 2024 Jun 28. doi: 10.1038/s41375-024-02322-7. PMID: 38942785. (#Co‐corresponding author)

  • Yang M, Ma Z, Wang C, Agca MC, Liu H, Huang K, Glage S, Rumpel R, Gerbaulet A, Roers A, Liu X, Noyan F, von Neuhoff N, Ganser A, Liu L, Yun H#, Li Z#. Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD. Leukemia. 2024 Jun;38(6):1437-1439. doi: 10.1038/s41375-024-02259-x. PMID: 38720016. (#Co‐corresponding author)

  • Yun H#, Vohra S, Lara-Astiaso D, Huntly BJP#. Multiomics data integration to revealchromatin remodeling and reorganization induced by gene mutational synergy. STAR Protocols. 2022 Oct 13;3(4):101770. doi: 10.1016/j.xpro.2022.101770. PMID: 36242770. (#Co‐corresponding author)

  • Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D, Horton SJ, Agrawal-Singh S, Meduri E, Basheer F, Marando L, Gozdecka M, Dovey OM, Castillo-Venzor A, Wang X, Gallipoli P, Müller-Tidow C, Osborne CS, Vassiliou GS, Huntly BJP. Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. Nat Genet. 2021 Oct;53(10):1443-1455. doi: 10.1038/s41588-021-00925-9. PMID: 34556857.

  • Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P, Huntly BJP. Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. Blood. 2019 Dec 12;134(24):2195-2208. doi: 10.1182/blood.2019001553. PMID: 31515253.

  • Heuser M, Yun H, Thol F. Epigenetics in myelodysplastic syndromes. Semin Cancer Biol. 2018 Aug:51:170-179. doi: 10.1016/j.semcancer.2017.07.009. PMID: 28778402. (Review)

  • Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A, Chan WI, Sasca D, Yiangou L, Osaki H, Basheer F, Gallipoli P, Burrows N, Erdem A, Sybirna A, Foerster S, Zhao W, Sustic T, Petrunkina Harrison A, Laurenti E, Okosun J, Hodson D, Wright P, Smith KG, Maxwell P, Fitzgibbon J, Du MQ, Adams DJ, Huntly BJP. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol. 2017 Sep;19(9):1093-1104. doi: 10.1038/ncb3597. Epub 2017 Aug 21. PMID: 28825697.

  • Sharma A*, Yun H*, Jyotsana N, Chaturvedi A, Schwarzer A, Yung E, Lai CK, Kuchenbauer F, Argiropoulos B, Görlich K, Ganser A, Humphries RK, Heuser M. Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia. 2015;29(1):157-68. doi: 10.1038/leu.2014.162. PMID: 24957708. (*equal contribution)

  • Yun H, Damm F, Yap D, Schwarzer A, Chaturvedi A, Jyotsana N, Lübbert M, Bullinger L, Döhner K, Geffers R, Aparicio S, Humphries RK, Ganser A, Heuser M. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica. 2014 Sep;99(9):1456-64. doi: 10.3324/haematol.2013.101386. PMID: 24895338.

  • Heuser M, Yun H, Berg T, Yung E, Argiropoulos B, Kuchenbauer F, Park G, Hamwi I, Palmqvist L, Lai CK, Leung M, Lin G, Chaturvedi A, Thakur BK, Iwasaki M, Bilenky M, Thiessen N, Robertson G, Hirst M, Kent D, Wilson NK, Göttgens B, Eaves C, Cleary ML, Marra M, Ganser A, Humphries RK. Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell. 2011 Jul 12;20(1):39-52. doi: 10.1016/j.ccr.2011.06.020. PMID: 21741595.

  • more ORCID https://orcid.org/0000-0001-8714-205X